Replies to post #2473 on Axim Biotechnologies Inc (AXIM)

[TexasMarvL]

The CDC published the AXIM study??
Wish I had more dry powder.

BTW, I reserve the right to NOT sell my shares for just $1 (as I have previously stated), if #ImmunoPass is actually approved.

If #ImmunoPass is actually approved, the share price might surprise us.

[Devolution]

REALLY good stuff, as this ties in nicely the current political environment with AXIM's Immunopass test.

Bottom Line: Dr. Lake (who works at AXIM) has found (through his studies via the joint efforts of AXIM and Arizona State University) by using the Immunopass test kit, that one out of four (25%) of the 2 dose mRNA vaccine recipients do not respond well enough to the vaccinations (based on their antibody levels, as determined using Immunopass), and that a 3rd dose is necessary of any of the current vaccines out there to bring that 25% up to the appropriate antibody level of the rest of the vaccinated population.

This is documentable, SCIENTIFIC EVIDENCE that supports Booster shots for at least 25% of the vaccinated population, and the best way to determine if you are in that 25% is to use the Immunopass test kit to determine your specific reaction to the vaccine regiment.

Whether you personally believe in vaccination or booster shots, doesn't matter, as this is the first real SCIENTIFICALLY PROVABLE evidence that supports the POLITICAL environment.

A very nice step forward for Immunopass.

Using AXIM’s rapid neutralizing antibody test, Dr. Douglas Lake and Alexa Roeder, co-lead authors of the study, reported that 25% of two-dose RNA vaccine recipients did not generate high levels of neutralizing antibodies (<50% neutralization). They called this group “vaccine poor responders.” Fortunately, a third dose converted these vaccine poor responders into strong responders with an average of 20-fold increase in neutralizing antibody levels two to four weeks after their third dose.

“As many as 25% of people do not know they did not make high levels of protective antibodies after their second dose,” said Dr. Lake. “It doesn’t matter which vaccine you get as a third dose, but it does matter that you get a third dose. Everyone has a right to know how well their vaccine worked.”

“Our research team has been hard at work since the pandemic started to study how we can effectively detect neutralizing antibody levels,” said John Huemoeller, CEO of AXIM Biotech. “I am thankful that the CDC sees value in the work that we have done to understand the vaccine’s impact and hope that they continue to recognize the importance of understanding our levels of neutralizing antibodies as well as the work that AXIM is doing to make that possible for the general public.”